Proficio Capital Partners LLC Acquires New Stake in Medpace Holdings, Inc. $MEDP

Proficio Capital Partners LLC acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 910 shares of the company’s stock, valued at approximately $482,000.

A number of other large investors also recently bought and sold shares of MEDP. Johnson Financial Group Inc. purchased a new stake in shares of Medpace in the second quarter valued at about $27,000. Elyxium Wealth LLC purchased a new position in Medpace during the fourth quarter worth about $30,000. Jones Financial Companies Lllp purchased a new position in Medpace during the second quarter worth about $30,000. Allied Private Wealth LLC acquired a new stake in Medpace in the second quarter valued at about $31,000. Finally, Kilter Group LLC acquired a new stake in Medpace in the second quarter valued at about $31,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

MEDP opened at $611.57 on Friday. The business’s fifty day moving average is $562.52 and its two-hundred day moving average is $493.80. The company has a market cap of $17.07 billion, a price-to-earnings ratio of 35.85, a PEG ratio of 2.76 and a beta of 1.15. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same quarter last year, the business posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Insider Buying and Selling at Medpace

In other Medpace news, Director Brian T. Carley sold 5,000 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total value of $3,043,150.00. Following the sale, the director owned 27,825 shares of the company’s stock, valued at $16,935,129.75. This represents a 15.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO August J. Troendle sold 4,000 shares of the stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $620.03, for a total transaction of $2,480,120.00. Following the completion of the sale, the chief executive officer owned 540,544 shares in the company, valued at $335,153,496.32. This represents a 0.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 129,963 shares of company stock valued at $79,364,624 in the last quarter. Insiders own 20.50% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Truist Financial boosted their target price on Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $535.00 price target on shares of Medpace in a report on Thursday, July 23rd. TD Cowen lifted their price target on Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Royal Bank Of Canada upped their price objective on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Finally, Weiss Ratings upgraded Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. Three investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, Medpace presently has an average rating of “Hold” and a consensus target price of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.